Compare Illinois Tool Works Inc. (ITW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Illinois Tool Works Inc. is far larger — about 34.8× Recursion Pharmaceuticals Inc's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ITW | RXRX | |
|---|---|---|
Market Cap | $74.38B | $2.14B |
Volume | 1,125,477 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $299.60 | $6.79 |
52-Week Low | $241.07 | $2.84 |
Typical Hold Time | 67 Days | 22 Days |
Enterprise Value | $83.23B | $1.66B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $261.15, down 2.24% on the day, with a bearish technical signal from moving averages. The company demonstrates strong profitability with a 19.39% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its status as a Dividend King, having raised its dividend to $1.72 per share, with a forward yield of approximately 2.57%.
The outlook is mixed; strong fundamentals and a consensus price target of $280.14 suggest upside potential, but a high P/E ratio of 23.65 and bearish technical indicators indicate near-term pressure. Key risks include economic sensitivity and rising debt levels, while institutional buying provides some support.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
